What factors drove the changes in Kenvue's revenue and profit?

What is Kenvue's latest dividend and current dividend yield?

What is Kenvue's gross profit margin?

What were the key takeaways from Kenvue's earnings call?

What guidance did Kenvue's management provide for the next earnings period?

What were the key takeaways from Kenvue’s earnings call?

What is the market's earnings forecast for Kenvue next quarter?

What is the revenue and EPS growth rate for Kenvue year over year?

- **Revenue decline accelerates**: Q2 organic sales down 4.2% YoY, driven by allergy season weakness and inventory destocking.
- **Strategic reset underway**: 4 new senior hires, focus on 41 core brands, and $150M tariff mitigation plan.
- **Key growth drivers**: Neutrogena Face recovery (+12% U.S. consumption), Tylenol 12Q share gains, and Nicorette international expansion.
- **2025 Outlook**: Adjusted EPS guidance lowered to $1.00-$1.05, reflecting $0.07 headwind from strategic price investments.

**【CEO Summary Section】**
- Interim CEO Kirk Perry emphasized the need for operational simplification and execution excellence to address underperformance. Key priorities include:
  - **Leadership refresh**: 4 new senior hires in 3 months, including Chief Technology & Data Officer Mike Wondrasch.
  - **Focus on core assets**: 41 of 115 brands drive 75%+ of sales; 1% of SKUs account for 1% of revenue.
  - **Execution improvement**: Targeting flawless go-to-market execution in top markets (10 biggest brands/10 biggest markets account for 67%/75% of sales).
  - **Consumer-centric strategy**: Rebuilding brand equity through innovation (e.g., Tylenol's new Dye-Free formula) and health care professional engagement.

**【CFO Financial Commentary】**
- Q2 2025 Results:
  - Organic sales declined 4.2% YoY, driven by:
    - Self Care (-5.9%): Seasonal allergy weakness (U.S. allergy incidence down 7.7%, China category down) despite ZYRTEC share gains.
    - Skin Health & Beauty (-3.7%): U.S. sun care category softness offset by Neutrogena Face consumption recovery.
    - Essential Health (-2.4%): U.S. mouthwash share decline despite Wash Your Mouth campaign launch.
  - Adjusted EPS: $0.29 (vs. $0.32 YoY), impacted by strategic price investments and separation-related costs.
  - Margins: Adjusted operating margin contracted 10bps to 22.7%, gross margin down 70bps to 60.9% due to input cost inflation.
- Revised 2025 Guidance:
  - Organic sales: Low single-digit decline (vs. prior flat guidance).
  - Adjusted EPS: $1.00-$1.05 (down from prior $1.10-$1.20 range).
  - Key risks: Tariffs ($150M annualized impact), macro uncertainty, inventory destocking.

**【Q&A Key Highlights】**
- **Execution Timeline**: Kirk Perry expects to see sequential improvement in consumer share metrics within 3-6 months, starting with e-commerce and Listerine Total Care.
- **Complexity Reduction**: 1/3 of SKUs generate 1% of sales; 1/3 of brands drive 75% of sales. Strategic review evaluating brand portfolio rationalization.
- **Tariff Impact**: $150M annualized impact, partially offset by supply chain diversification.
- **Skin Health & Beauty Turnaround**: Neutrogena Face consumption growth in U.S., OGX innovation success (#1 launch YTD).

Kenvue, Inc. (KVUE) Q2 2025 Earnings Call Transcript

- **Q1 Resilience**: Organic sales decline (-1.2%) in line with expectations, driven by China destocking and U.S. price investments. Tylenol gains 11th straight quarter of share growth.
- **Skin Health Turnaround**: Neutrogena Gen Z penetration +30bps; Aveeno U.S. growth >10x industry rate. Q2 launches to drive consumption recovery.
- **Tariff Headwinds**: $150M annualized impact from U.S. tariffs; 2/3 from China. 2025 EPS expected flat YoY due to $0.02 FX drag.
- **CFO Transition**: Amit Banati's 30+ years CPG experience to accelerate growth through strategic cost management and innovation.


**【CEO Opening Remarks】**
- Q1 organic sales declined 1.2% YoY, in line with full-year outlook, due to destocking in China and strategic price/trade investments in the U.S.
- Self-Care segment showed resilience, with Tylenol gaining 11th consecutive quarter of value/volume share, driven by breakthrough campaigns and innovation.
- Skin Health & Beauty faced headwinds from destocking in China and U.S. price investments, but consumption outpaced organic sales growth in Q1.
- CFO transition announced: Paul Ruh to support transition, Amit Banati to join as new CFO on May 12, bringing 30+ years of CPG experience.

**【CFO Financial Highlights】**
- Q1 adjusted gross margin: 60.0% (down 20bps YoY due to volume deleverage, tariffs, and price investments).
- Adjusted operating margin: 19.8% (down 220bps YoY due to brand investments).
- Adjusted net income: $465M; adjusted EPS: $0.24 (including $0.02 FX headwind).
- 2025 Outlook: Organic sales growth 2-4%, adjusted EPS flat YoY due to $150M tariff impact and FX headwinds.

**【Q&A Key Takeaways】**
- **Tariff Mitigation**: $150M annualized impact from U.S. tariffs; 2/3 from China (finished goods), 1/3 raw materials. Actions include dual sourcing, RGM, and supply chain optimization.
- **Skin Health Momentum**: Neutrogena Gen Z penetration +30bps; Aveeno U.S. growth >10x industry rate. Q2 launches include Neutrogena face/body care innovations.
- **Supply Chain Resilience**: <10% China exposure; dual-sourcing reduces risk. Retailers value Kenvue's resilient supply chain in uncertain environment.
- **2025 Execution**: Back-half acceleration driven by lapping Q1/Q2 headwinds, new innovations (e.g., Tylenol waterproof bandages), and improved execution.


Kenvue (KVUE)-8 May 25-2025 Q1 Earnings call transcript

- **2024 Performance**: 1.5% organic growth, 60.4% gross margin, $1.14 EPS. Challenges: flu season underperformance (-2pts to Q4 growth), China distributor issues.
- **2025 Outlook**: 2%-4% growth, Q1 -1% to -3%, H2 acceleration. $350M cost savings, 20%+ brand investment, 90%-100% cash conversion target.
- **Key Drivers**: Innovation (+40% 2025 launches), US price investments, EMEA/Latin America skin health growth, flu season normalization in H2.

**【CEO Summary Section】**
- Kenvue reported 1.5% organic sales growth in 2024, missing expectations due to lower-than-expected cough, cold, and flu incidences and distributor disruptions in China. Adjusted diluted EPS of $1.14 met guidance.
- Adjusted gross margin expanded 200 basis points to 60.4%, driven by operational efficiency and $350M in annualized cost savings by 2026. Brand investment increased 20% to $1.2B, with 10.6% of sales allocated to advertising.
- 2025 outlook: 2%-4% organic sales growth, with Q1 facing a 3-4% headwind from destocking and price investments, followed by acceleration in the second half.

**【CFO Financial Commentary】**
- Q4 2024: Organic sales +1.7%, adjusted EPS $0.26. Full-year adjusted net income $2.2B, within guidance.
- 2025 financials: Net sales expected to decline 1%-up 1% due to 3% currency headwind. Adjusted operating margin to expand, supported by $350M in cost savings and disciplined reinvestment.
- Free cash flow conversion target of 90%-100% remains, with 2025 investments in TSA exits and digital capabilities.

**【Q&A Key Points】**
- **2025 Q1 Challenges**: Low flu season in US and China, plus distributor corrections in Asia Pacific, will cause low-single-digit organic sales decline. Headwinds moderate in Q2, with stronger growth in H2.
- **Skin Health & Beauty Recovery**: EMEA and Latin America driving global growth, with US Neutrogena regaining face care leadership. 2025 innovation pipeline includes 40% more products, targeting premiumization and adjacency extensions.
- **Tariff Mitigation**: Playbook ready to activate, including alternate sourcing and pricing adjustments, but 2025 guidance excludes tariff impacts.
- **FX Risk Management**: Hedging programs in place; 2025 EPS expected to grow slightly ahead of organic sales, despite mid-single-digit currency headwind.

Actual	0.32	0.31	0.31	0.28	0.32	0.28	0.26	0.24	0.29	0.28	0.27
Forecast	0.3017	0.3128	0.283	0.2541	0.2757	0.2723	0.2568	0.2275	0.2817	0.2602	0.2204
Surprise	+6.07%	-0.90%	+9.54%	+10.19%	+16.07%	+2.83%	+1.25%	+5.49%	+2.95%	+7.61%	+22.50%

Actual	4.01B	3.92B	3.67B	3.89B	4.00B	3.90B	3.66B	3.74B	3.84B	3.76B	3.78B
Forecast	3.96B	3.91B	3.78B	3.79B	3.93B	3.92B	3.76B	3.68B	3.85B	3.82B	3.68B
Surprise	+1.31%	+0.23%	-3.10%	+2.73%	+1.84%	-0.53%	-2.61%	+1.73%	-0.36%	-1.46%	+2.83%

KVUE

KVUE fundamentals

KVUE Q4 2025 Earnings

Earnings Call

You can ask Aime

KVUE

KVUE fundamentals

KVUE Q4 2025 Earnings

Earnings Call

KVUE Earnings Call Summary for Q4/20255:00 PM on Feb 17, 2026

KVUE Earnings Call Summary for Q3/20258:30 AM on Nov 6, 2025

KVUE Earnings Call Summary for Q2/20258:30 AM on Aug 7, 2025

KVUE Earnings Call Summary for Q1/20258:00 AM on May 8, 2025

KVUE Earnings Call Summary for Q4/20248:00 AM on Feb 6, 2025

You can ask Aime